in the Greater Mekong Sub-region

Similar documents
ARTEMISININ RESISTANCE IN THE GREATER MEKONG SUBREGION

DELAYING ARTEMISININ RESISTANCE: FRAMING POLICY RESPONSE FOR AN EMERGING PUBLIC HEALTH CONCERN

The global challenge of antimalarial drug resistance

Status report on artemisinin resistance

Artemisinin resistance: global situation, update and next steps. WHO Webinar

Status report on artemisinin resistance

Guyana Shield Meeting on the Implementation of the Framework for Artemisinin Resistance Prevention, Containment, and Elimination in South America

ARTEMISININ RESISTANCE

Malaria Consortium Asia provides technical assistance to countries in developing winning proposals for resource mobilisation in the GMS,

Counterfeit medical products

PROGRAM BRIEF: PSI/MYANMAR. Improving Malaria Case Management in the Private Sector: Artemisinin Monotherapy Replacement (AMTR) Project. psi.

REGIONAL ARTEMISININ MALARIA INITIATIVE (RAI)

ASEAN Regulatory Harmonisation and Approval Process

Containing artemisinin resistance of Plasmodium falciparum in Myanmar: achievements, challenges and the way forward

Malaria Consortium Myanmar

Second APEC Ministers' Conference on Regional Science & Technology Cooperation (Seoul, Korea, Nov 13-14, 1996) JOINT COMMUNIQUÉ

ASIA PACIFIC LEADERS MALARIA ALLIANCE MALARIA ELIMINATION ROADMAP

Health R&D. Thailand Country Study:

Draft global strategy on public health, innovation and intellectual property

Global strategy and plan of action on public health, innovation and intellectual property

Affordable Medicines Facility-malaria (AMFm): Innovative Financing for Better Access

JOB DESCRIPTION. Department: Technical Length of contract: 3 years renewable. Reporting to: Chief of Party Direct reports: Numbers to be confirmed

INNOVATING FOR RESULTS

Tapan Ray Director General Organisation of Pharmaceutical Producers of India ALCAN PACKAGING UNIVERSITY OCT 8, LONAVALA

The case for quality

Towards malaria elimination: ADB-supported work at Myanmar FDA

Draft Plan of Action Chair's Text Status 3 May 2008

models for malaria elimination in the Greater Mekong Sub Region Lisa White, MAEMOD, Mahidol Oxford Tropical Medicine

The 21 st APEC Small and Medium Enterprises Ministerial Meeting Joint Ministerial Statement. Nanjing, China September 5, 2014

WHO/PRP/11.1 ENGLISH ONLY MEDIUM-TERM STRATEGIC PLAN INTERIM ASSESSMENT

2014/SOM2/049 Agenda Item: 2.1. CTI Chair s Report. Purpose: Consideration Submitted by: CTI Chair

Counterfeit, Falsified and Substandard Medicines

Cambodia: From Control to Elimination

Analysis of the Regulatory Capacity to Assure the Quality of Antimalarial Medicines in Selected Countries of the Greater Mekong Subregion of Asia

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

The Third APEC Ministers Conference on Regional Science and Technology Cooperation. Mexico City, October 21-23, 1998 DRAFT JOINT COMMUNIQUE

alaria2012 Malaria in the Asia-Pacific: Challenges and opportunities for access to quality malaria medicines and other technologies Paper 3

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

KEY FINDINGS. Antony Ellman. Malcolm Cutler. FSC Development Services. Natural Resources Institute

Susan Schneegans, Editor, UNESCO Science Report

FRAMEWORK FOR ARTEMISININ RESISTANCE PREVENTION, CONTAINMENT, AND ELIMINATION IN SOUTH AMERICA

The 26 th APEC Economic Leaders Meeting

The Global Alliance for Chronic diseases (GACD)

CCM-Thailand Round 9 malaria proposal to the GFATM. Snapshot information to interested partners

International Regulatory Harmonization and Medical Technology Innovation. Some personal thoughts

Elements of a global strategy and plan of action

The New Delhi Communiqué

OECD-ASEAN Business Statement

WHO Malaria Policy Advisory Committee (MPAC) meeting

PACIFIC POSSIBLE CONSULTATIONS OF CONCEPT

Why is CRVS so important?

Science, Technology & Innovation Policy: A Global Perspective. Dr Lauren Palmer Australian Academy of Technological Sciences & Engineering (ATSE)

Improving Institutional Capacity for Health Research and Use

ACP/84/047/02 Final Cape Town, 28 July 2002 PAHD Dept. CAPE TOWN DECLARATION ON RESEARCH FOR SUSTAINABLE DEVELOPMENT

CER-ASEAN Integration Partnership Forum. CER-ASEAN participation in global frameworks for international recognition and harmonisation of measurement

Colombia on the Frontier of Biomedicine. Zagaya

Good Things Increasing

Biocommercialization: Providing Enabling Policy Environments

Honolulu, Hawaii November 11, Statement

Interim Report on the Heiligendamm Process at the G8 Summit in Hokkaido Toyako 7 to 9 July 2008

Policy Partnership on Science, Technology and Innovation Strategic Plan ( ) (Endorsed)

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective

Trans-Pacific Partnership Agreement: The Empowerment of Small and Medium-Sized Enterprise in Malaysia

December Eucomed HTA Position Paper UK support from ABHI

10 th APEC TRANSPORTATION MINISTERIAL MEETING 7 th October 2017 Port Moresby, Papua New Guinea Ministerial Statement

ICT and Innovation for Structural Change

Strengthening civil registration and vital statistics systems - a necessity for the region to overcome socioeconomic and health challenges

Health Innovation Manchester

GLOBAL HEALTH R&D FOR THE POST-2015

Wael Al-Delaimy MD, PhD. President, Society for Advancement of Science and Technology in the Arab World

SUSTAINABLE OCEAN INITIATIVE: KEY ELEMENTS FOR THE PERIOD

ASEAN ICT Policies: R&D Priority and Master Plan

DHA piperaquine as an eradication tool in Myanmar

IPEG Convenor Report to CTI

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

Counterfeit Medicines Toolkit 4. Information about the International Medical Products Anti-Counterfeiting Taskforce (IMPACT)

SECOND GLOBAL SYMPOSIUM ON HEALTH SYSTEMS RESEARCH SCIENCE TO ACCELERATE UNIVERSAL HEALTH COVERAGE

Intellectual Property Management Medicines for Malaria Venture. Life Sciences Symposium WIPO 15 December 2008

Are Asia-Pacific Advances in Higher Education & Research Sustainable?

NEWS RELEASE. Life sciences companies tout their expertise in India

Ipca Laboratories Limited

Innovation policy mixes and implications on HEIs - emerging conclusions from the OECD innovation policy reviews

Science Policy and Social Change. December 2003

2015/SOM2/PPSTI/001 Agenda Item: 2. Draft Agenda. Purpose: Consideration Submitted by: Chair

Scenario Development Process

OECD Science, Technology and Industry Outlook 2008: Highlights

Ministerial Conference on Nuclear Science and Technology: Addressing Current and Emerging Challenges Vienna, November 2018

Driving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China

G7 SCIENCE MINISTERS COMMUNIQUÉ

Franco German press release. following the interview between Ministers Le Maire and Altmaier, 18 December.

GLOBAL MALARIA DIAGNOSTIC AND ARTEMISININ TREATMENT COMMODITIES DEMAND FORECAST

1. About ACCESS-SMC Project

Update on Progress Implementing the LSIF Anti- Counterfeit Medicines Action Plan

UNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015

5 TH MANAGEMENT SEMINARS FOR HEADS OF NATIONAL STATISTICAL OFFICES (NSO) IN ASIA AND THE PACIFIC SEPTEMBER 2006, DAEJEON, REPUBLIC OF KOREA

TBT Provisions in RTAs: Do they go beyond the TBT Agreement?

EPO, SCENARIOS FOR THE FUTURE, 2007

SPEECH BY DEPUTY MINISTER OF EDUCATION, SCIENCE AND TECHNOLOGY HON. CHIKUMBUTSO HIWA, M.P.

PTB TWG-ICS- Session 3: Specific domains of respectful newborn care: The role of Civil Registration and Vital Statistics Systems

Global Nonwoven Summit

Transcription:

in the Greater Mekong Sub-region 05 07 August 2013

Towards Multi-sectoral Actions to Combat Malaria Drug Resistance in the Greater Mekong Sub-region Dr. Leonard Ortega Regional Adviser, Malaria WHO South East Asia Region

Improved malaria situation in the GMS, 2002-2010 Annual Parasite Index, GMS, 2002 Annual Parasite Index, GMS, 2010

Marked reduction of malaria deaths in the GMS, 2002-2010 Malaria mortality, 2002 Malaria mortality, 2010

Artemisinin resistance in the GMS is a global threat Source: Bustos MD et al. The Southeast Journal of Tropical Medicine and Public Health Volume 44 (Supplement 1), 2013.

The evolution of drug-resistant malaria (Plowe CV. Trans R Soc Trop Med Hyg 11 Dec 2008) Low Grade Pyrimethamine Resistance CHLOROQUINE SULFADOXINE-PYRIMETHAMINE Clinically Significant Pyrimethamine Resistance

Artemisinin resistance: some contributing factors Irrational use of anti-malarial medicines Use of oral artemisinin monotherapies Sub-standard / fake / counterfeit malaria medicines Poor access to health services Low coverage of malaria control interventions

Global Plan for Artemisinin Resistance Containment Action Pillars Contain or eliminate artemisinin resistance where it already exists Prevent artemisinin resistance where it has not yet appeared 1 2 3 4 Stop the spread of resistant parasites Increase monitoring & surveillance to evaluate the AR threat Improve access to diagnostics & rational treatment with ACTs Invest in artemisinin resistancerelated research 5 Motivate action and mobilize resources

Emergency Response to Artemisinin Resistance (ERAR) in the Greater Mekong Sub-region Regional Framework For Action Fifteen Actions in 4 Action Areas: 1)Full coverage of interventions in priority areas 2)Tighter coordination and management of field operations 3)Better information for artemisinin resistance containment 4)Regional oversight and support

ERAR Regional Framework for Action (1)

ERAR Regional Framework for Action (2)

Containment of Artemisinin Resistance in the GMS Tier 1 - Areas for which there is credible evidence of artemisinin resistance Tier II: Areas with significant inflow of people from tier I areas, including those immediately bordering tier I; Tier 3: Areas with no evidence of artemisinin resistance and limited contact with tier I areas

High-level political commitments (1) Increasing efforts within ASEAN to address drug resistant malaria July 2012 - ASEAN Health Ministers Meeting, and ASEAN+3 Health Ministers Meeting agreed that antimalarial resistance is a regional concern November 20 - Declaration of the 7 th East Asia Summit on Regional Responses to Malaria Control and Addressing Resistance to Antimalarial Medicines Endorsed by Heads of State/Government of ASEAN Member States, plus Australia, People s Republic of China, Republic of India, Japan, Republic of Korea, New Zealand, Russian Federation and the United States of America

High-level political commitments (2) Malaria 2012: Saving Lives in the Asia-Pacific October 2012, hosted by Government of Australia Adopted Consensus on malaria control and elimination in the Asia-Pacific, Creation of Asia-Pacific Leaders Malaria Alliance (APLMA) Two Taskforces 1) access to quality medicines and other technologies 2) regional financing for malaria and other communicable disease threats

Moving Forward: Translating political commitments into multi-sectoral actions Suggestions on key areas for multi-sectoral collaboration: Ensuring quality, availability and rational use of ACTs Addressing malaria prevention and control among migrant populations and ethnic communities Scaling up massively and rapidly the key interventions towards malaria elimination in the GMS

Malaria drug resistance: threatens lives and a major barrier for malaria elimination The road towards malaria elimination is long and difficult but together we can make it! Thank you!